All News
Filter News
Found 667 articles
-
Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
-
Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases
7/25/2019
This latest publication underscores the potential for rapid deployment of Inovio's DNA vaccines.
-
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
-
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
-
Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates
7/16/2019
Inovio Pharmaceuticals, Inc. announced that it has sharpened its corporate strategy to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop fast-to-market product candidates.
-
Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)
7/8/2019
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN).
-
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
6/26/2019
If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.
-
The intention is to focus its research efforts on cancer, immunology, rare diseases and vaccines. The changes will result in the loss of 466 jobs in the two countries.
-
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
6/10/2019
In addition to the development of CELLECTRA 3PSP, the new award will fund the investigation of DNA vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the new device.
-
Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial
5/21/2019
Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations
-
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
5/16/2019
Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100
-
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
5/15/2019
Inovio Pharmaceuticals Inc. and Plumbline Life Sciences announced a collaboration to co-develop a novel animal health vaccine for African swine fever virus.
-
“With today’s FDA approval, Eylea has once again set a high bar for the treatment of diabetic eye diseases,” stated George D. Yancopoulos, president and chief scientific officer at Regeneron.
-
Ionis reports first quarter 2019 financial results
5/9/2019
Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2019 and recent business highlights.
-
Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results
5/9/2019
Inovio Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019.
-
Adimab Expands Research Agreement with Regeneron
5/8/2019
Adimab, LLC, the leading provider of antibody discovery and optimization technology, announced the expansion of an earlier multi-target research agreement with Regeneron Pharmaceuticals.
-
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
5/6/2019
The procedure of certification of quality and non-clinical data involves an assessment of the available data in view of future registration and the related European Scientific Data Requirements, not including any clinical data or benefit-risk assessment.
-
Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
5/1/2019
Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019.
-
Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal
4/18/2019
Data demonstrates tumor-clearing ability of Inovio's dBiTE
-
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress
4/17/2019
The Vaccine Industry Excellence Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders.